Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Govt Launches Panel to Respond to Red Yeast Rice Issue
The Japanese government on March 27 launched a committee made up of four relevant ministries and agencies to discuss ways to handle products using beni-koji, or red yeast rice, as cases of health damages are being reported for supplements containing…
To read the full story
Related Article
- Hong Kong Fund Oasis Sues Kobayashi Execs over Beni-Koji Scandal
April 8, 2025
- Kobayashi Pharma Scraps Medium-Term Biz Plan Due to Beni-Koji Scandal
February 12, 2025
- Kobayashi Pharma to Revamp Management under New President
January 22, 2025
- Puberulic Acid Determined as Cause of “Beni-Koji” Health Damages
September 19, 2024
- Kobayashi Pharma Replaces Management after Beni-Koji Scandal
July 24, 2024
- More Unexpected Substances in Kobayashi’s Beni-Koji Supplements: MHLW
April 22, 2024
- Fanconi Syndrome Found in Majority of Health Damages Tied to Beni-Koji Supplements
April 10, 2024
- Kobayashi Factory Inspected over Beni-Koji Health Issue
April 1, 2024
- “Puberulic Acid” in Beni-Koji Supplements; Kobayashi Wants to Keep Healthcare Biz
April 1, 2024
- Beni-Koji Issue: MHLW Requests Self-Inspections to Purchasers of Kobayashi’s Red Rice Yeast
March 29, 2024
- One Dead after Taking Kobayashi’s Red Yeast Rice Pills
March 27, 2024
- Kobayashi’s Beni Koji Health Damage Reports Trigger Knock-On Recalls
March 27, 2024
- Hospitalized Cases Tied to Kobayashi Pharma’s Supplements Now Up to 26
March 26, 2024
- Kobayashi Pharma Recalls Supplements on Reports of Kidney Disorders
March 25, 2024
REGULATORY
- Japan to Ease Olanzapine Diabetes Contraindication for Antiemetic Use
July 31, 2026
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…